CDMO and CRO selection should be evaluated as a regulatory and quality decision first, and a procurement decision second, using inspection history and oversight model design as the evaluative frame.
White Paper
Your CDMO Is Part of Your Regulatory Strategy
Related Resources
All Resources
post
Understanding FDA’s Real-Time Oncology Review (RTOR Medical Abbreviation) Program
Read More
white-paper
FDA CRLs Reveal a Pattern: Biologic Control Strategy Issues Drive Delays and Rejections
Read More
post
Building the Future of Breakthrough Therapies Together
Read More
post
When the Only Drug Runs Out: Lessons from the Bicillin® L-A Recall
Read More
Let's move from science to success.
Let’s Talk